Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Adherence and the Patient Acceptability of Zomacton Treatment With the Zomajet Vision X Device

Trial Profile

Evaluation of the Adherence and the Patient Acceptability of Zomacton Treatment With the Zomajet Vision X Device

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 15 May 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Somatrogon (Primary)
  • Indications Somatotropin deficiency; Turner's syndrome
  • Focus Therapeutic Use
  • Acronyms ZOMAXEPT
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 11 May 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrial.gov.
    • 18 Nov 2014 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018 as reported by ClinicalTrial.gov record.
    • 16 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top